Applying Multidisciplinary Expertise and Heterogeneous Skills in Clinical Practice: Transforming Non-Small Cell Lung Cancer Treatment with Immunotherapy


David P. Carbone, MD, PhD
Professor of Internal Medicine
Director of the James Thoracic Oncology Center
Ohio State University Wexner Medical Center (OSUMC)
Barbara J. Bonner Chair in Lung Research
The Ohio State University
Columbus, OH

David Planchard, MD, PhD
Gustave Roussy
Head of Thoracic Cancer Group
Department of Medical Oncology
Thoracic Group
Villejuif, France


This program addresses current evidence-based perspectives in first-line management of advanced non-small cell lung cancer (NSCLC) in the first-line setting based on biomarkers, tumor histology, and patient-specific factors. By analyzing current clinical trial data and patient subgroups, clinicians will gain an understanding of therapeutic strategies, including checkpoint inhibitor monotherapy and checkpoint inhibitors in combination with chemotherapy. Given updates in the early-line management of NSCLC, it is crucial for multidisciplinary health care professionals to maintain awareness of novel combinations and potential adverse events associated with therapy, including immune-related adverse events. This program will emphasize best practices in multidisciplinary management, adverse event monitoring, and ongoing care to optimize therapeutic outcomes.


This activity is designed to meet the educational needs of global medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.


  • Apply medical society recommendations for the first-line treatment of patients with advanced NSCLC with no targetable mutations
  • Describe the recognition and management of immune-related adverse events in patients with advanced NSCLC
  • Review the latest immunotherapy clinical trial results for both monotherapy and chemotherapy combinations for the first-line treatment of patients with advanced NSCLC


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.


In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


David P. Carbone, MD, PhD Consulting, advisory role or lectures: Curio Science, G1 Therapeutics, Glaxo-Smith Kline, Iovance Biotherapeutics, Janssen, Jazz, Johnson & Johnson, Merck/EMD Serono, Merck KGaA, Mirati Therapeutics, Novartis, Regeneron, Sanofi, Intellisphere, Roche Taiwan, AstraZeneca, Pfizer, Arcus Biosciences, Roche, BMS Israel, AbbVie, Merk & Co., Inc. , Pfizer Egypt, Genentech, PPD Development, InThought, Onc Live, Novocure, OncoHost, and Merk US.
David Planchard, MD, PhD Consulting, advisory role or lectures: AstraZeneca, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Janssen, Pfizer, Roche, Pierre-fabre,
Takeda, ArriVent, Mirati, Seagen
Clinical trials research as principal or co-investigator (Institutional financial interests): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, Abbvie, Janssen, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen
Travel, Accommodations, Expenses: AstraZeneca, Roche, Novartis, Pfizer

All relevant financial relationships have been mitigated.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
  • Michael Page, PharmD, RPh Medical Director for Med Learning Group, has no relevant disclosures.
  • Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
  • Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
  • Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


There are no fees for participating and receiving CE credit for this enduring activity.

In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.

Your certificate will be provided as a downloadable file.


Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at


Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024

Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.


Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

Healthcare Business Review Award

We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!

This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.

Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.

#TopHealthEducationProvider #MedLearningGroup #HealthcareBusinessReview #MedicalEducation

Best of America Small Business Awards
Best Website

The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal:

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.